Abstract:
PURPOSE: A 5-(substituted alkylaminomethyl)isoxazole based compound as T-type calcium channel blocker is provided to have excellent activity as an antagonist of T- type calcium ion channel. CONSTITUTION: A 5-(substituted alkylaminomethyl)isoxazole based compound as T-type calcium channel blocker is represented by chemical formula 1. The encephalopathy therapy and for prevention agent selected from epilepsy, depression, Parkinson's disease, dementia, sleep disorder, an agent for cancer treatment and prevention, an agent for heart disease treatment and prevention selected from hypertensive, cardiac arrhythmia, angina, myocardial infarction, congestive heart failure, pharmaceutical composition for alleviating pain selected from neuropathic pain and chronic and acute pain includes a compound represented by chemical formula 1.
Abstract:
본 발명은 신규한 벤조아릴우레이도 화합물, 및 이의 퇴행성 뇌질환 예방 또는 치료에 있어서의 용도에 관한 것으로, 보다 상세하게는, 화학식 1의 구조를 갖는 벤조아릴우레이도 화합물, 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 예방 또는 치료용 조성물에 관한 것이다. 상기 퇴행성 뇌질환은 알츠하이머, 치매, 파킨슨병, 뇌졸중, 아밀로이드증, 픽 질환 (Pick's disease), 루게릭병, 헌팅턴병, 크로이츠펠트-야콥(Creutzfeld-Jakob)병 등일 수 있다. [화학식 1]
Abstract:
A pharmaceutical composition for preventing and treating the disease related to the central nervous system, and a food composition are provided to obtain the effect on emesis, nausea, alcoholism, drugs abuse, depression, compulsion neurosis, anxiety, etc. A pharmaceutical composition for preventing and treating the disease related to the central nervous system comprises a quinoline derivative compound represented by the formula 1 or its pharmaceutically acceptable salt as an active ingredient, wherein R1 is H, a C1-C6 alkyl group, a phenyl group or a benzyl group; R2 is a heterocyclic group selected from morpholine, pyrrolidine and piperidine; the phenyl group or the benzyl group can be substituted with a substituent selected from a halogen atom, a C1-C6 alkyl group and a C1-C6 alkoxy group; and n is an integer of 1-6.
Abstract:
A method for preparing a novel D-erythro-2-deoxy-2,2-difluoro-1-oxoribose compound is provided to synthesize the compound with high purity and high yield selectively, which is able to be used as an intermediate for preparing beta-2,2-difluoro nucleoside. A D-erythro-2-deoxy-2,2-difluoro-1-oxoribose compound is represented by the formula(1), wherein R1 is piperonyloyl, 2,3-dimethoxybenzoyl or 2,4-dimethoxybenzoyl; and R2 is benzoyl, biphenylcarbonyl, naphthoyl, benzyloxycarbonyl, para-methoxy benzyloxycarbonyl, or para-nitrobenzyloxycarbonyl substituted by a substituent selected from the group consisting of acetyl, monochloroacetyl, dichloroacetyl, pivaloyl, nitro, methyl, trifluoromethyl, chloro, fluoro, hydroxy and methoxy. A method for preparing the compound of the formula(1) comprises the steps of: reacting a compound represented by the formula(4) with piperonyloyl, 2,3-dimethoxybenzoyl or 2,4-dimethoxybenzoyl compound to prepare a compound represented by the formula(3); reacting the compound of the formula(3) with an acid to prepare a compound represented by the formula(2); and protecting 5-hydroxy of the compound of the formula(2). In the formulae(2) to (4), R is the same as defined above.
Abstract:
PURPOSE: A novel macrolide compound having an inhibiting activity for the growth of Helicobacter pylori is provided, which is not easily decomposed by gastric acid. CONSTITUTION: The macrolide compound is represented by formula (1), in which R1 is hydrogen, 4-methoxy phenoxy methyl, 2-methoxy phenoxy methyl or methoxy ethoxy methyl; R2 is hydrogen, acyl or lower alkoxy; R3 is the same or different and hydrogen or acyl; and Q and W form oxo together or independently -OR4 and hydrogen, wherein R4 is hydrogen. It has an inhibiting activity for the growth of Helicobacter pylori which causes several stomach diseases.
Abstract:
PURPOSE: Provided are novel pyridopyrimidine derivatives which inhibit phosphodiesterase IV activity and TNF production. Also, provided are preparing process thereof and a pharmaceutical composition containing the same. CONSTITUTION: The novel pyridopyrimidine derivative is represented by the formula(1), wherein R1 is C1-3 lower alkyl, C3-7 cycloalkyl, cycloalkyloxy, cycloalkyl amino, cycloalkyl lower alkyl, C1-3 lower alkoxy, formyl, hydroxy lower alkyl or carboxyalkyl; R is hydrogen, methyl, C3-7 lower alkyloxy, phenyl, benzyl, substituted phenyl(wherein a substituent group includes cyano, halogen, carboxylalkyl, nitro, methyl, trihalogenated ethyl or alkyloxy; and substitution site can be ortho-, meta-, or para- site), alkyloxy, C3-7 lower alkyloxy ethyl, benzyloxy, benzyloxyethyl, phenyloxyethyl, carboxyalkyl or cyano group; and R4 is hydrogen or methyl group, provided that R2 and R3 are not the same.
Abstract:
PURPOSE: A novel macrolide compound having an inhibiting activity for the growth of Helicobacter pylori is provided, which is not easily decomposed by gastric acid. CONSTITUTION: The macrolide compound is represented by formula (1), in which R1 is hydrogen, 4-methoxy phenoxy methyl, 2-methoxy phenoxy methyl or methoxy ethoxy methyl; R2 is hydrogen, acyl or lower alkoxy; R3 is the same or different and hydrogen or acyl; and Q and W form oxo together or independently -OR4 and hydrogen, wherein R4 is hydrogen. It has an inhibiting activity for the growth of Helicobacter pylori which causes several stomach diseases.